News

James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer research.

In a recent study, single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced <em>BRAF</em>-positive ovarian cancer.

Denosumab (Xgeva) was shown to be noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma.

In an interview with<em> Targeted Oncology</em>, Kimberly L. Blackwell, MD, discusses the latest therapeutic developments for patients with HER2-positive breast cancer while providing insight on the hurdles that still remain.

Pembrolizumab (Keytruda) has received FDA approval for the frontline treatment of patients with metastatic non&shy;&ndash;small cell lung cancer (NSCLC) whose tumors have &ge;50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer.

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

Findings of the phase III KEYNOTE-045 trial showed pembrolizumab (Keytruda) demonstrated improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer.

Nationally recognized oncologist Nancy E. Davidson, MD, has accepted the position of Executive Director of Clinical Oncology at the Fred Hutch/University of Washington (UW) Cancer Consortium in Seattle, Washington. Davidson was previously Director of the the University of Pittsburgh Cancer Institute (UPCI).

The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.

Brad S. Kahl, MD, sheds light on the distinctive clinical features of MCL.

Richard R. Furman, MD emphasizes that physicians should follow their best independent judgment regarding therapy selection in CLL, regardless of FDA approval.

According to phase I data presented at the 2016 ESMO Congress, a&nbsp;novel HER2-targeting antibody-drug conjugate showed promising antitumor activity across multiple tumor types, including HER2-postive breast cancer.

Men with bone-metastatic castration-resistant prostate cancer (mCRPC) appeared to derive additional benefits from treatment with radium-223 with concomitant bone-targeted therapies.

Confirming the results of an earlier phase II study, findings from the FALCON trial showed first-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with hormone receptor (HR)-positive advanced breast cancer.

The PDGFR&alpha; antagonist olaratumab (Lartruvo) has been granted an accelerated approval from the FDA&nbsp;in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS) who are not candidates for radiotherapy or surgery.

Atezolizumab has received FDA approval for the treatment of patients with metastatic NSCLC who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring <em>EGFR</em> or <em>ALK</em> abnormalities.&nbsp;

Rimas Lukas, MD, discusses the next steps in glioblastoma research, as well as the potential use of IDO inhibitors in the treatment of GBM, and recent studies showing promise in the field.

Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

The positive opinion for the BCL-2 inhibitor has been sent to the European Commission, which usually issues its final approval decision within 2 to 3 months of the CHMP recommendation.

Frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma,&nbsp;a final analysis of the OS data from the KEYNOTE-006 trial showed.

ASCO-CAP recently released new guidelines for the use of FISH testing for HER2 in breast cancer, due to discrepancies in HER2-testing results.

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

Steve Coutre, MD, discusses how he determines which CLL treatment option is best for which patient, the advantage of treating patients with ibrutinib over chemoimmunotherapy, and new oral agents currently being investigated in the space.

Results from the KRISTINE^&nbsp;and NSABP B-41&nbsp;trials provided the latest data on the use of pertuzumab, trastuzumab, ado-trastuzumab emtansine, and lapatinib for the neoadjuvant treatment of patients with HER2-positive breast cancer.

William J. Gradishar, MD, summarizes the need for new strategies to alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.